New COVID-19 Variant PJ.2.1: Symptoms, Spread, Vaccine Findings and Key Facts

A new variant of SARS-CoV-2, named PJ.2.1, was first identified in Ontario, Canada in May 2026. This variant has been identified in several countries and research was conducted into its genetic and virological features. Research published in the Journal of Infection in October 2026 found that the spike protein may increase cellular entry via the ACE2 receptor. However, this could not be verified in the lab to cause more severe disease or increased transmissibility. To date, this variant has not been identified as a variant of interest or variant under monitoring according to the World Health Organization.

What is the PJ.2.1 variant of COVID-19?

This variant of SARS-CoV-2 is classed as a saltation variant by researchers due to it containing a relatively high number of genetic changes.

According to research by Markus Hoffmann et al., this variant originated from MC.10.1.7, a descendant of the JN.1 lineage. The first documented sample was taken in Ontario, Canada, on 2nd May 2026. This research was published in the journal of Infection on 24th October 2026.

Where has PJ.2.1 been identified?

Since being identified in Canada, this variant has been identified in other provinces within the country as well as the United States. Researchers have also identified this variant in parts of Europe, Asia and Oceania.

As stated in the research paper,

• Canada: Ontario, Alberta, British Columbia, New Brunswick
• United States: First identified in New York City on 30th June 2026, it has since been identified in several other states.
• Europe: France and Spain; Localised outbreaks were seen in several regions.
• Asia: Singapore and Israel
• Oceania: Australia and New Zealand.

This shows that this variant has spread internationally.

PJ.2.1 in Ontario

Evidence has been found that this variant is becoming more prevalent. Public Health Ontario released a genomic surveillance report in November 2026 showing the following data:

Period	Percentage of PJ.2.1 Cases
28th June – 25th July 2026	1.1%
26th July – 22nd August 2026	3.5%
23rd August – 19th September 2026	16.9%
20th September – 17th October 2026	25.2%

This means that in the latest 4 weeks, this variant has been the most commonly identified variant in sequenced cases. In total, 523 cases were sequenced with 132 of them being identified as PJ.2.1.

It should be noted that these figures only show the proportion of cases sequenced that are the PJ.2.1 variant. It should also be noted that Public Health Ontario advise these results may not reflect the whole population and sequencing results may not be complete in recent months.

Why is this variant spreading? What does the research show?

Research was conducted into the genetic changes in the spike protein.

The spike protein binds to a protein on the surface of human cells called ACE2 (Angiotensin-Converting Enzyme 2). Researchers found that this variant displayed improved cellular entry compared to the reference variant LP.8.1.

The study also looked into whether the variant could evade antibodies from vaccination. It was found that there was not a significant increase in antibody evasion compared to most other variants tested.

Specifically, this variant was shown to be neutralised by antibodies from people WHO had received an adapted LP.8.1 vaccine. It was found that the neutralisation sensitivity was 1.8 times less than the reference variant LP.8.1.

Overall, this shows that this variant may have increased ACE2 binding and cellular entry. However, this cannot be verified in the lab to cause increased transmissibility or more severe disease.

What are the symptoms of PJ.2.1?

There are no confirmed symptoms associated with this variant of the virus. People infected with this variant may experience typical symptoms of COVID-19.

Common symptoms of current variants of the virus include fever, chills and sore throat, as outlined by the World Health Organisation. Other symptoms may include,

• Cough
• Runny or blocked nose
• Headache
• Muscle and joint pain
• Fatigue and weakness
• Shortness of breath
• Loss/change of taste/smell
• Nausea, vomiting and diarrhoea.

Symptoms can vary between individuals and may be similar to symptoms from influenza, common cold and other respiratory infections. Therefore symptoms can’t be reliably used to identify this variant. Testing will need to be done to determine the infection and genomic sequencing can identify the exact variant.

Is this variant More Dangerous Than Previous variants?

There isn’t enough evidence to conclude that this variant causes more severe disease, hospitalizations or increased risk of death compared to other variants.

The main focus of this research was to look at the genetic characteristics of this variant, cellular entry and antibody neutralization. There wasn’t enough evidence to show that this variant causes more severe disease.

It’s important to understand the difference between transmissibility, immune evasion and severity of disease. A variant can become more prevalent but not cause more severe disease. There needs to be more clinical and epidemiological evidence to determine the risks of this variant.

Those at higher risk of severe complications from COVID-19 include older adults, those with weakened immune systems and underlying health conditions.

What is the WHO stance on this variant?

The WHO monitors variants of SARS-CoV-2. They classify variants as,

• Variant of concern (VOC): Variants that have significant impacts on public health, including more severe disease and impact on health care services.
• Variant of interest (VOI): Variants which have genetic changes and evidence they may impact characteristics of the virus.
• Variant under monitoring (VUM): Variants which are being monitored as they have genetic changes or evidence of potential public health importance.

As of 27th July 2026, JN.1 was identified as a variant of interest and several variants were identified as variants under monitoring including XFG, NB.1.8.1, PQ.16.1.1 and BA.3.2. This variant was not identified as any of these. Other variants were identified as variants under monitoring according to the WHO dashboard between 6th September – 4th October 2026.

This variant should not be confused as a variant of concern.

Are current vaccines effective against this variant?

Encouraging evidence was found regarding antibodies. It was found that antibodies from those WHO had received an adapted LP.8.1 vaccine could neutralize this variant.

However, this doesn’t indicate how effective a vaccine would be at preventing infection and severe disease. It was not found how effective this vaccine would be against this variant clinically.

Getting vaccinated against COVID-19 is still an important step in reducing your risk of severe disease. The WHO recommends getting vaccinated according to your risk. Those at higher risk of severe disease should speak to their healthcare professionals to find out what vaccinations and boosters are recommended.

How is India monitoring new variants of COVID-19?

India monitors genetic changes of SARS-CoV-2 using the Indian SARS-CoV-2 Genomics Consortium (INSACOG). This involves genomic sequencing from various laboratories.

Whole genome sequencing can help identify new variants and monitor changes in the virus. This helps public health authorities monitor the spread of SARS-CoV-2.

There is no evidence to state that this variant has been identified in India.

Prevention From New Variant

• When a new variant has been identified, it is important to stay aware and take correct health precautions. General precautions to take include:
• Stay at home and limit contact with others if you have respiratory symptoms.
• Keep hands clean and increase ventilation.
• Consider wearing a well-fitting face mask in crowded, poorly ventilated areas.
• Make sure you’re up to date with your vaccinations.
• If you’re experiencing symptoms, seek medical advice.
• Seek urgent medical advice if you’re experiencing any of the following symptoms:
• Breathing difficulties.
• Persistent chest pain or pressure.
• Confusion or inability to stay conscious.